This page identifies the research gap for developing next-generation TSPO PET ligands that overcome current limitations including rs6971 polymorphism sensitivity, limited specificity for microglial phenotypes, and suboptimal signal-to-noise ratios.
- [^11C]PK11195: Gold standard but high non-specific binding, short half-life, variable quantification
- [^11C]PBR28: High affinity but 3-10x lower binding in low-affinity binders (LABs)
- [^11C]DPA-713: Improved signal-to-noise but still polymorphism-sensitive
- [^18F]FEPPA: Longer half-life but LAB sensitivity
- [^18F]GE-180: Reduced polymorphism sensitivity but still not ideal for all patients
-
Polymorphism-Independent Tracers
- Gap: No truly polymorphism-independent tracer for universal use
- Need: Tracers with equal binding across rs6971 genotypes
- Priority: Critical
- Status: Active development
-
Microglial Phenotype Selectivity
- Gap: Current tracers cannot distinguish pro-inflammatory vs anti-inflammatory microglia
- Need: Tracers that bind preferentially to specific microglial activation states
- Priority: High
- Status: Early research
-
Improved Signal-to-Noise
- Gap: Limited contrast between inflamed and non-inflamed regions
- Need: Tracers with higher specific-to-nonspecific binding ratio
- Priority: High
- Status: Optimization ongoing
-
Faster Kinetics
- Gap: 60-90 minute scanning protocols limit clinical practicality
- Need: Tracers enabling 30-minute scanning protocols
- Priority: Medium
- Status: Some candidates
-
Theranostic Potential
- Gap: No TSPO ligands combining imaging and therapeutic functions
- Need: Tracers that can be linked to therapeutic moieties
- Priority: Low
- Status: Conceptual
- Design new TSPO ligands with reduced LAB binding
- Use computational modeling to predict polymorphism effects
- Test candidate compounds in vitro
¶ Phenotype-Selective Ligands
- Identify microglial state-specific TSPO conformations
- Develop selective ligands for M1 vs M2-like microglia
- Validate in disease models
- Multi-center trials of next-generation tracers
- Standardization of acquisition and analysis protocols
- Regulatory pathway development